Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives

References

• GLOBOCAN 2012 v10Cancer incidence and mortality worldwide: IARC CancerBase no 11 [updated 2012] Available from: http://globocan.iarc.frAccessed January 30, 2016
   Google Scholar
• ZnaorALortet-TieulentJLaversanneMInternational variation and trend in renal cell carcinoma incidence and mortalityEur Urol20156751953025449206
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon α, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Guidelines: Kidney Cancer Version IFort Washington, PANCCN2016
   Google Scholar
• EscudierBPortaCSchmidingerMRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol2014254956
   Web of Science ®Google Scholar
• Stephan MichelMWalterVMaria deSSWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)J Clin Oncol201432Suppl 4 abstr 393
   Web of Science ®Google Scholar
• MotzerRBarriosCHKimTMRecord-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)J Clin Oncol201331Suppl abstr 4504
   PubMed Web of Science ®Google Scholar
• HengDYSignorovitchJSwallowEComparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observationalPLoS One2014912e11426425493562
   PubMed Web of Science ®Google Scholar
• AlimohamedNLeeJSrinivasSA population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaClin Genitourin Cancer2014124e127e13124485801
   PubMedGoogle Scholar
• EscudierBGoreMSequencing therapy in metastatic renal cell cancerSemin Oncol201340446547123972710
   PubMed Web of Science ®Google Scholar
• JonaschESignorovitchJELinPLTreatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practicesCurr Med Res Opin201430102041205024983741
   PubMed Web of Science ®Google Scholar
• Hu-LoweDDZouHYGrazziniMLNonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3Clin Cancer Res200814227272728319010843
   PubMed Web of Science ®Google Scholar
• SonpavdeGHutsonTERiniBIAxitinib for renal cell carcinomaExpert Opin Investig Drugs2008175741748
   PubMed Web of Science ®Google Scholar
• AkazaHFukuyamaTAxitinib for the treatment of advanced renal cell carcinomaExpert Opin Pharmacother201415228329724328549
   PubMed Web of Science ®Google Scholar
• HutsonTELesovoyVAl-ShukriSAxitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trialLancet Oncol201314131287129424206640
   PubMed Web of Science ®Google Scholar
• RixeOBukowskiRMMichaelsonMDAxitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyLancet Oncol200781197598417959415
   PubMed Web of Science ®Google Scholar
• RiniBIDe La Motte RougeTHarzstarkALFive-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinibClin Genitourin Cancer201311210711423391371
   PubMed Web of Science ®Google Scholar
• LiJYangCWangSFirst-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinomaAnticancer Res201434105643564725275068
   PubMed Web of Science ®Google Scholar
• VickersMMChoueiriTKRogersMClinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyUrology201076243043420223508
   PubMed Web of Science ®Google Scholar
• EscudierBSzczylikCPortaCGoreMTreatment selection in metastatic renal cell carcinoma: expert consensusNat Rev Clin Oncol20129632733722473096
   PubMed Web of Science ®Google Scholar
• HutsonTEEscudierBEstebanERandomized phase III trial of temsirolimus versus sorafenib as second-line therapy after suni-tinib in patients with metastatic renal cell carcinomaJ Clin Oncol201432876076724297950
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBTomczakPAxitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialLancet Oncol201314655256223598172
   PubMed Web of Science ®Google Scholar
• RiniBIWildingGHudesGPhase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaJ Clin Oncol200927274462446819652060
   PubMed Web of Science ®Google Scholar
• ZamaINHutsonTEElsonPSunitinib rechallenge in metastatic renal cell carcinoma patientsCancer2010116235400540621105118
   PubMed Web of Science ®Google Scholar
• EscudierBMichaelsonMDMotzerRJAxitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialBr J Cancer2014110122821282824823696
   PubMed Web of Science ®Google Scholar
• Al-MarrawiMYRiniBIHarshmanLCThe association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsTarget Oncol20138320320923300029
   PubMed Web of Science ®Google Scholar
• HengDYMacKenzieMJVaishampayanUNPrimary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapyAnn Oncol20122361549155522056973
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol19991782530254010561319
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol200927345794579919826129
   PubMed Web of Science ®Google Scholar
• MichaelsonMDStadlerWMPredictive markers in advanced renal cell carcinomaSemin Oncol201340445946423972709
   PubMed Web of Science ®Google Scholar
• QiWHeAShenZYaoYIncidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysisBr J Clin Pharmacol201376334835723617405
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOFouadMRisk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib, or regorafenib: an updated systematic review and comparative meta-analysisCrit Rev Oncol Hematol201492319420725028151
   PubMed Web of Science ®Google Scholar
• HamnvikORChoueiriTKTurchinAClinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathwayCancer2015121231131925236375
   PubMed Web of Science ®Google Scholar
• IzzedineHEderhySGoldwasserFManagement of hypertension in angiogenesis inhibitor-treated patientsAnn Oncol200920580781519150949
   PubMed Web of Science ®Google Scholar
• CopurMSObermillerAAn algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibitionClin Colorectal Cancer201110315115621855035
   PubMed Web of Science ®Google Scholar
• KatsiVIoannisZManolakouSAnti-VEGF anticancer drugs: mind the hypertensionRecent Pat Cardiovasc Drug Discov201496372
   Google Scholar
• ChenYRiniBIMotzerRJEffect of renal impairment on the pharmacokinetics and safety of axitinibTarget Oncol Epub9242015
   Web of Science ®Google Scholar
• TomitaYUemuraHFujimotoHKey predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinomaEur J Cancer201147172592260221889330
   PubMed Web of Science ®Google Scholar
• DaimonMKatoTKainoWThyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinomaJpn J Clin Oncol201242874274722628612
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• RiniBIGarrettMPolandBAxitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisJ Clin Pharmacol201353549150423553560
   PubMed Web of Science ®Google Scholar
• RiniBIMelicharBUedaTAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialLancet Oncol201314121233124224140184
   PubMed Web of Science ®Google Scholar
• RiniBIMelicharBFishmanMAxitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinomaAnn Oncol20152671372137725701454
   PubMed Web of Science ®Google Scholar
• LarkinJFishmanMWoodLAxitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomesAm J Clin Oncol201437439740323357974
   PubMed Web of Science ®Google Scholar
• BracardaSCastellanoDProcopioGAxitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studiesExpert Opin Drug Saf201413449751024641566
   PubMed Web of Science ®Google Scholar
• RiniBISchillerJHFruehaufJPDiastolic blood pressure as a biomarker of axitinib efficacy in solid tumorsClin Cancer Res201117113841384921531811
   PubMed Web of Science ®Google Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst2011103976377321527770
   PubMed Web of Science ®Google Scholar
• Rodríguez-AntonaCGarcía-DonasJConstitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinomaPharmacogenomics201213141621163323148638
   PubMed Web of Science ®Google Scholar
• BrennanMWilliamsJAChenYTortoriciMPithavalaYLiuYCMeta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokineticsEur J Clin Pharmacol201268564565522170007
   PubMed Web of Science ®Google Scholar
• EscudierBRiniBIMotzerRJGenotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinomaClin Genitourin Cancer2015134328337.e325816720
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular characterization of clear cell renal cell carcinomaNature20134997456434923792563
   PubMed Web of Science ®Google Scholar
• JosephRKapurPSerieDClear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expressionJ Urol2016195118018726300218
   PubMed Web of Science ®Google Scholar
• HsiehJChenDWangPChenYRedzematovicAMarkerMIdentification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): results from RECORD-3J Clin Oncol201533Supplabstr 4509
   Web of Science ®Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191803181326406148
   PubMed Web of Science ®Google Scholar
• ChoueiriTEscudierBPowlesTCabozantinib versus everolimus in advanced renal-cell carcinomaN Engl J Med2015373191814182326406150
   PubMed Web of Science ®Google Scholar